SOW
NKTR icon

State of Wyoming’s Nektar Therapeutics NKTR Stock Holding History

State of Wyoming’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
2,379
+1,452
+157% +$106K 0.02% 1130
2026
Q1 		$66.7K Buy
+927
New +$52.8K 0.01% 1432

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State of Wyoming's NKTR Position: Q2 2026 in Review

State of Wyoming increased its Nektar Therapeutics (NKTR) stake by 157% in Q2 2026, buying an estimated $106K and bringing the position to 2,379 shares worth $166K. The position accounts for 0.02% of the portfolio, ranked #1130.

State of Wyoming first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • State of Wyoming held 2,379 shares of Nektar Therapeutics worth $166K as of Q2 2026.
  • State of Wyoming bought 1,452 Nektar Therapeutics shares in Q2 2026, an estimated $106K.
  • Nektar Therapeutics made up 0.02% of State of Wyoming's portfolio in Q2 2026, its #1130 holding.
  • State of Wyoming first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.